Neurocrine Biosciences (NBIX) Projected to Announce Quarterly Earnings on Monday

Key Points

• Neurocrine Biosciences is expected to report Q3 2026 results after Monday’s market close. Analysts forecast earnings of $1.93 per share on $1.05 billion in revenue, with the earnings call scheduled for 4:30 p.m. ET.
• The company’s latest quarter exceeded expectations, with EPS of $2.85 versus the $1.65 consensus estimate and revenue of $959 million, up 39.5% year over year.
• Analysts remain broadly positive, with a “Moderate Buy” consensus rating and an average price target of $201.14, although insiders have sold 4,387 shares worth about $720,855 over the past 90 days.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) is expected to announce its Q3 2026 results after the market closes on Monday, November 2nd. Analysts expect the company to announce earnings of $1.93 per share and revenue of $1.05 billion for the quarter. Parties can check the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Monday, November 2, 2026 at 4:30 PM ET.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last issued its earnings results on Friday, July 31st. The company reported $2.85 earnings per share for the quarter, topping analysts' consensus estimates of $1.65 by $1.20. Neurocrine Biosciences had a return on equity of 22.43% and a net margin of 20.91%. The company had revenue of $959.00 million for the quarter, compared to analyst estimates of $891.16 million. During the same period in the prior year, the firm earned $1.65 earnings per share. Neurocrine Biosciences's revenue for the quarter was up 39.5% on a year-over-year basis. On average, analysts expect Neurocrine Biosciences to post $7.72 EPS for the current fiscal year and $9.28 EPS for the next fiscal year.

Neurocrine Biosciences Price Performance

Shares of NBIX opened at $142.70 on Monday. Neurocrine Biosciences has a 12-month low of $122.14 and a 12-month high of $186.12. The business's fifty day moving average is $147.49 and its 200 day moving average is $153.95. The stock has a market cap of $14.51 billion, a P/E ratio of 20.92, a P/E/G ratio of 0.63 and a beta of 0.40.

Insider Activity at Neurocrine Biosciences

In related news, CFO Matt Abernethy sold 2,311 shares of the company's stock in a transaction on Monday, September 14th. The stock was sold at an average price of $157.20, for a total transaction of $363,289.20. Following the completion of the sale, the chief financial officer owned 42,808 shares in the company, valued at approximately $6,729,417.60. This represents a 5.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Leslie Norwalk sold 1,250 shares of the stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $182.01, for a total value of $227,512.50. Following the completion of the sale, the director directly owned 1,588 shares of the company's stock, valued at $289,031.88. The trade was a 44.05% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 4,387 shares of company stock valued at $720,855 over the last 90 days. Insiders own 4.60% of the company's stock.

Analyst Ratings Changes

A number of brokerages have commented on NBIX. Royal Bank Of Canada restated an "outperform" rating and set a $198.00 price target on shares of Neurocrine Biosciences in a research note on Tuesday, September 8th. Canaccord Genuity Group raised their price objective on shares of Neurocrine Biosciences from $200.00 to $210.00 and gave the company a "buy" rating in a research note on Monday, August 3rd. Piper Sandler lifted their price objective on shares of Neurocrine Biosciences from $207.00 to $210.00 and gave the company an "overweight" rating in a report on Friday, July 31st. BMO Capital Markets reduced their price objective on shares of Neurocrine Biosciences from $164.00 to $150.00 and set a "market perform" rating for the company in a report on Monday, October 12th. Finally, Wedbush boosted their target price on shares of Neurocrine Biosciences from $185.00 to $194.00 and gave the stock an "outperform" rating in a research report on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $201.14.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is a San Diego-based biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and psychiatric disorders. The company's research programs target conditions in which treatments may address significant unmet medical needs.

Neurocrine's leading product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor approved in the United States for the treatment of tardive dyskinesia and chorea associated with Huntington's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.